



2011

Evaluation of Activated Partial Thromboplastin Time (aPTT) Reagents for Application in Biomedical Diagnostic Device Development

Magdalena Dudek
Dublin City University

Leanne F. Harris
Dublin Institute of Technology, leanne.harris@dit.ie

Anthony J. Killard
University of the West of England

Follow this and additional works at: <http://arrow.dit.ie/scschbioart>



Part of the [Biology Commons](#)

Recommended Citation

Dudek, M., Harris, L. and Killard, A. (2011) Evaluation of activated partial thromboplastin time (aPTT) reagents for application in biomedical diagnostic device development. *International Journal of Laboratory Haematology*, 2011 Jun;33(3):272-80. doi:10.1111/j.1751-553X.2010.01283.x.

This Article is brought to you for free and open access by the School of Biological Sciences at ARROW@DIT. It has been accepted for inclusion in Articles by an authorized administrator of ARROW@DIT. For more information, please contact yvonne.desmond@dit.ie, arrow.admin@dit.ie, brian.widdis@dit.ie.





Evaluation of activated partial thromboplastin time (aPTT) reagents for application in biomedical diagnostic device development

Journal:	<i>International Journal of Laboratory Hematology</i>
Manuscript ID:	IJLH-12-09-0241
Manuscript Type:	Original Article
Date Submitted by the Author:	11-Dec-2009
Complete List of Authors:	Dudek, Magdalena Harris, Leanne Killard, Anthony; Dublin City University, Biomedical Diagnostics Institute
Keywords:	Anticoagulants, Coagulation, Coagulation Inhibitors, Heparin, Laboratory Automation



TITLE PAGE**Pages:** 27.**Illustrations:** 4 Figures, 2 Tables.

Evaluation of activated partial thromboplastin time (aPTT) reagents for application in biomedical diagnostic device development

Running title: aPTT reagents for application in biodevices

Magdalena M. Dudek, Leanne Harris and Anthony J. Killard

Biomedical Diagnostics Institute, National Centre for Sensor Research, Dublin City University, Dublin 9, Ireland.

Corresponding Author

Dr. Anthony J. Killard,

Biomedical Diagnostics Institute, National Centre for Sensor Research, Dublin City University, Dublin 9, Ireland.

Tel.: 0035317007871

Fax: 0035317007873

E-mail address: tony.killard@dcu.ie

KEYWORDS

aPTT, clotting time, thrombin generation assay, stability, heparin sensitivity.

1
2
3
4
5 SUMMARY

6
7 The most commonly used test for monitoring heparin therapy is the activated partial
8 thromboplastin time (aPTT). The performance of available aPTT reagents varies
9 significantly. The aim of this study was to assess the suitability of dried aPTT reagents
10 for the purpose of monitoring unfractionated heparin dose-response in diagnostic
11 devices. Ten reagents were analysed in terms of their performance in liquid and in dried
12 form after 24 h and 14 days. The ability to reduce the natural plasma clotting time (CT)
13 and their sensitivity to heparin was assessed. The thrombin generation assay was the
14 method of choice. All reagents resulted in significant reductions in CT. Liquids returned
15 more rapid CTs in comparison to dried reagents. Most reagents were more sensitive to
16 heparin in dried, rather than in liquid form. Dried reagents based on kaolin as a surface
17 activator were notably more effective in achieving rapid CT, while reagents composed
18 of silica and synthetic phospholipids were the most sensitive to heparin. Identification
19 of the most suitable aPTT assay reagent for incorporation into a diagnostic device
20 platform was achieved based on dried reagent stability and responsiveness to heparin.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

There has been growing interest in the development of miniaturized, point-of-care diagnostic devices (Khandurina and Guttman, 2002). There is an increasing requirement for reliable point-of-care devices for monitoring the effect of drugs which regulate blood coagulation (Khan, 2009). This in turn leads to an increased demand for highly concentrated and optimized formulations of active ingredients capable of inducing a rapid clotting response in a low volume test sample. Since the first application of partial thromboplastin time (aPTT) for monitoring anticoagulant therapy (Struver and Bittner, 1962), it has become the most popular test for heparin dose monitoring (Gawoski et al., 1987) and is regarded as the most reliable and commonly used test (Kitchen et al., 1996) for heparin dosage adjustment in long term therapy and pre-thrombotic monitoring (Bowers and Ferguson, 1993). There have been several automated devices developed to monitor aPTT, e.g. the CoaguCheck[®] Pro. In general, such devices contain dry formulations that selectively induce the clotting process. The accuracy and reliability of the results are highly influenced by the quality of the dried chemistry. There are a growing number of ready-to-use aPTT reagent kits available in liquid or lyophilized forms. A number of studies have identified that aPTT reagents vary significantly in their responsiveness to heparin (Kitchen et al., 1999, Banez et al., 1980). Different aPTT reagents often return different aPTT values with normal patient plasmas. There is an urgent need for the standardization of aPTT-based monitoring systems for heparin therapy in clinical settings (Poller et al., 1989, Kitchen et al., 1996). The varying responsiveness of aPTT reagents is dependent upon the composition of particular constituents of the formulation. These contain animal or plant extracts as sources of phospholipids (partial thromboplastin) combined with a surface activator such as kaolin,

1
2
3
4 celite, silica, ellagic acid, dextran sulphate or carrageenans. Negatively charged
5
6 substances supported by phospholipids bring about the surface-dependent activation of
7
8 factor XII which is the first step of the contact activation pathway leading to the
9
10 eventual formation of the insoluble fibrin clot (Griffin and Cochrane, 1979). Both, the
11
12 source and the concentration of phospholipids have been highlighted as important
13
14 factors in assay behaviour, e.g. a decreased phospholipid concentration can lead to an
15
16 increased heparin sensitivity of the reagent (Ts'ao et al., 1998, Kitchen et al., 1999).
17
18 Stevenson et al. documented that the lipid phase concentration may differ by 300 times
19
20 between some commercially available aPTT reagents (Stevenson et al., 1986).
21
22 Advances in technology have led to the development of recombinant materials for use
23
24 in coagulation assays. Such defined and reproducible materials might help to control the
25
26 variation that exists within aPTT activated clotting response (Barrowcliffe and Gray,
27
28 1981, Triplett, 1982). Several reports provide a detailed characterization of aPTT
29
30 reagents (Stevenson et al., 1991, Kitchen et al., 1999, Martin et al., 1992). These are
31
32 extremely informative sources of data on aPTT reagent composition and performance in
33
34 clinical and laboratory settings. The differences in their sensitivity to heparin and lupus
35
36 antibodies have been shown (Eby, 1997, Manzato et al., 1998). However, there is very
37
38 little data regarding the use of available aPTT formulations for the purpose of diagnostic
39
40 device development. Due to a wide variety of aPTT products with different
41
42 formulations and physical characteristics, an assessment of the aPTT performance in
43
44 dried form and its stability upon prolonged storage time was needed. Evaluation of the
45
46 dried-surface reagents would allow selection of the most suitable activators to be
47
48 incorporated into a coagulation monitoring assay. The effect of resolubilization and
49
50 drying on their activity is of particular relevance.
51
52
53
54
55
56
57
58
59
60

1
2
3
4 The thrombin generation assay (TGA) was chosen as a tool for the comparison of the
5 ability of aPTT reagents to reduce natural plasma clotting time (CT) by measuring the
6 rate of thrombin generation (van Veen et al., 2008). This study includes a comparison of
7 a variety of aPTT formulations in (i) liquid, (ii) 24 h dried and (iii) 14 days dried forms.
8 These were analysed in terms of their ability to reduce plasma CT, stability upon
9 prolonged exposure to ambient conditions and responsiveness to heparin.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

MATERIALS AND METHODS

Materials

Ten aPTT reagents were studied (Table 1). All assays were performed using Hemosil plasma (0020003710, Instrumentation Laboratory, Italy/USA). The colorimetric thrombin substrate was H-D-Phenylalanyl-L-pipecolyl-L-arginine-p-nitroanilinedihydrochloride (S-2238, Chromogenix, Italy/USA) and was prepared by dilution 1:4 with Tris.HCl pH 8.3. Calcium chloride (CaCl₂) (100989) was from BioData (Netherlands/USA). Heparin sodium salt was from Sigma, Germany/USA (H0777-100KU), Greiner BioOne 96 well microassay plates (655096, Greiner BioOne, Germany) were used for all assays. All water was 18 MΩ or greater.

Thrombin Generation Assay

Assays were carried out using 96-well polystyrene microassay plates. Each test well (n = 5) contained 50 μL aPTT reagent, 50 μL plasma, 50 μL colorimetric substrate and 50 μL 25 mM CaCl₂. aPTT reagent was pre-incubated with plasma according to manufacturer recommendations. Subsequently, colorimetric substrate and CaCl₂ were added. Measurement was started immediately after CaCl₂ addition. The amount of generated thrombin was determined colorimetrically by measuring the release of *p*-nitroaniline (pNA) from the chromogenic substrate on a Tecan Infinite M200 (Tecan Group Ltd., Switzerland) at 405 nm with measurements made every 30 s for 1 h. TGA assays yielded absorbance profiles which related to the generation of thrombin following activation of the intrinsic clotting cascade. A positive thrombin control was also included in every assay where aPTT reagent was replaced with 50 μL of thrombin at a concentration of 3 U/mL (Sigma-Aldrich Inc.). aPTT reagents were analysed in

1
2
3
4 both liquid and dried forms, with the latter being evaluated at 24 h and 14 days
5 following drying. For drying, 50 μ L of aPTT reagent were pipetted into the 96 well
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

both liquid and dried forms, with the latter being evaluated at 24 h and 14 days following drying. For drying, 50 μ L of aPTT reagent were pipetted into the 96 well plates and left to dry under ambient laboratory conditions. The dried reagent was reconstituted in 50 μ L of water prior to analysis. Thrombin generation profiles for dried reagents at 24 h and 14 days were compared to those for liquid controls.

Reagents were analysed in terms of their sensitivity to heparin using spiked plasma samples. It has been shown that the response from *ex vivo* samples from patients on heparin therapy differs from *in vitro* plasma samples spiked with heparin (Jespersen et al., 1999, Van den Besselaar et al., 1990). However, heparin-spiked samples were used herein for the purpose of a performance comparison between reagents and not for the aPTT clinical reference standardization. Control plasma was spiked with heparin so that the final concentration in plasma was between 0 and 2 U/mL.

Data Analysis

The activity of the aPTT reagents was determined by their ability to reduce the natural plasma CT. Three methods of CT calculation were employed which were (i) the length of the lag time (LT), which was taken as the time prior to the occurrence of the thrombin burst (observed as a rapid increase in the measured absorbance) followed by a propagation phase (Wolberg, 2007), (ii) the area under the curve (AUC) and (iii) the time-to-peak (TTP). AUC was calculated from both raw (absorbance vs time) and differentiated (dAbs vs time) data. This reflects the total time for which thrombin exerts its enzymatic activity and is related to the endogenous thrombin potential. TTP was taken as the time point where the response profile reached a plateau and the increase in

1
2
3
4 absorbance ceased. This is related to initiation of thrombin production and propagation
5
6 and corresponds to the time required for the available substrate to be utilized (Wolberg,
7
8 2007). Analysis of these characteristic response profiles led to the determination of CT
9
10 based on LT. CT values were related to heparin concentration and the resulting
11
12 correlations provided useful information about the dry and liquid reagent sensitivity to
13
14 heparin. Inter- and intra-assay variation (CV) was also determined.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS

Clotting time extraction. Fig. 1 shows typical thrombin generation profiles for human plasma samples with and without activation by Cephalinex aPTT reagent. The thrombin generation profile of the blank control showed a LT greater than 1500 s, a rapid increase in absorbance and a plateau at about 2500 s. In most assays, corn trypsin inhibitor is added to prevent controls from clotting. However, as a control to assess the level of inter-assay variability, non-activated controls were used (Lo et al., 2005). The average control plasma LT for all assays was found to be 1943 s with a %CV of 15.6%. Addition of liquid Cephalinex aPTT reagent resulted in the rapid onset of the thrombin burst resulting in an indeterminate LT. The linear fluorescence response was reached at about 150 s, with the plateau being reached at approx. 200 s. In comparison, when reagent was dried, an increase in the LT of approx. 100 s was noted, which suggests that, for this reagent at least, drying did result in increased LT. However, there was little change in LT between 24 h and 14 days storage (LTs of around 300 s).

Fig. 1.

Several methods were employed to correlate the TGA output with the change in CT following incubation with heparin as shown for aPTT-SP in Fig. 2. Heparin plays a role in the positive-feedback inhibition of thrombin (Beguin et al., 1988) and was used here to obtain prolonged clotting times. LT and TTP calculations resulted in similar correlations between CT values and heparin dosage. LT values were predictably lower than the TTP values by the difference in rise time for the thrombin burst. Both these parameters were prolonged with increased heparin concentration. The correlation was close to linear for both methods with $R^2 \geq 0.986$. Calculation of the area under the curve

1
2
3
4 (AUC) was not found to be a useful tool in CT determination. No correlation between
5
6
7
8
9
10
11
12
13 calculated area values and heparin dose was found. LT was thus chosen as the most
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Fig. 2.

Comparison of aPTT reagent activities in liquid and dried forms

It has been established in many studies that commercially available aPTT reagents are effective for plasma CT reduction in their liquid form. However, an important parameter from the point of view of bioassay development is that reagents need to maintain their pro-coagulant properties upon long-term storage in a dehydrated state. The performance of aPTT reagents in their liquid and 24 h / 14 day dried forms was assessed by TGA according to their CT values (Fig. 3).

Fig. 3.

As expected, the performance of all aPTT reagents in their liquid forms was excellent. The liquid state was recommended by manufacturers to be used for plasma CT assays. CT values between 41 ± 12.8 s for C.K. Prest 2 and 161 ± 23.8 s for SynthASIL were obtained. In addition to comparisons of reagent activity in their liquid forms, the stability of the ready-to-use formulations was also assessed following drying and storage for 24 h and 14 days. Short term storage (24 h) did affect the activity of most reagents. CTs obtained for Platelin LS after 24 h were significantly prolonged, from 95 ± 21.3 s in liquid to 468 ± 15.9 s. CTs of dried reagents were at least twice as long as that for the equivalent liquid reagent: Alexin (85 ± 7.1 s to 180 ± 52.3 s), Cephalinex (110

1
2
3
4 ± 9.8 s to 288 ± 55 s), C.K. Prest 2 (41 ± 12.8 s to 96 ± 15.9 s), aPTT-P (72 ± 11.3 s to 218
5 ± 19.3 s) and aPTT-SA (83 ± 1.4 s to 184 ± 24.2 s) for liquid and 24 h dried CTs,
6
7 respectively. The only exception was aPTT-SP which proved to be perfectly stable after
8
9 24 h yielding a shortened CT over the liquid form by approx. 10 s.
10
11
12
13
14
15

16 In order to establish if the ability of the aPTT to activate clotting continued to
17 deteriorate with prolonged storage, additional tests were performed after 14 days. For
18 all reagents, the CT values gradually increased with one exception; Cephalinex returned
19 a CT of around 280 s for 24 h and 14 day measurements. The ability of Platelin LS and
20 Alexin to reduce the plasma CT decreased dramatically to 1566 ± 415.7 s and 850
21 ± 130.7 s for 14 days Platelin LS and Alexin, respectively. The effect of reagent
22 deterioration in the form of increased CT was expected to correlate with prolonged
23 storage. Such reagents would not be considered as suitable candidates for a dried matrix
24 of coagulation activators incorporated into a clot monitoring device. The addition of
25 stabilizing buffers, preservatives or special storage conditions could be beneficial in the
26 improvement of stability. However, the aim was to rapidly establish the activity of the
27 dried ready-to-use reagents in order to select the most stable formulations. The effect of
28 a diminished CT reduction was not as strongly manifest for the other eight reagents as it
29 was for Platelin LS and Alexin. CTs were between 200 ± 17.3 s for Dapttin to 438
30 ± 135.2 s for aPTT-P.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 The ideal dried formulation not only had to reduce the plasma CT efficiently and be
55 stable over a prolonged period of storage, but should also generate reproducible results
56 and so inter- and intra- variability was a factor of importance. The within-run %CV was
57
58
59
60

1
2
3
4 maintained at $\leq 15\%$ for all tested reagents ($n = 5$), while significant differences in the
5
6 inter-assay variability ($n = 3$) was noticed. It was observed that reagents that were more
7
8 affected by the storage time and conditions, resulting in a prolonged CT (in comparison
9
10 to a liquid control) were also the least precise (highest %CV for between-assay
11
12 variability). These were Platelin LS, Alexin, aPTT-P and aPTT-SA which yielded CTs
13
14 of 1566 s (26.5%), 850 s (15.4%), 438 s (30.9%) and 314 s (40.5%) respectively. The
15
16 remaining six reagents resulted in CTs < 300 s and %CV of less than 15%.
17
18
19
20
21

22 23 **Heparin sensitivity**

24
25 A striking variation in aPTT reagent sensitivity to thrombin inhibitors such as heparin
26
27 has been documented (Greaves, 2004). Performance of aPTT reagents is highly
28
29 dependent on the source and content of phospholipids as well as on the type and
30
31 concentration of surface activator that is supposed to serve a large surface area for
32
33 stimulation of kallikrein-like activity and initiation of coagulation. Several studies have
34
35 reported the association of aPTT reagent composition with variations in clotting
36
37 efficacy (Smeets et al., 1996, Neuenschwander et al., 1995) and responsiveness to
38
39 anticoagulant dosage (Ip et al., 2001, Kitchen et al., 1996). Herein, the effect of the
40
41 drying process and storage of the aPTT reagents was also evaluated for its effect on the
42
43 response to heparin in the TGA. Such data is of great importance for the development of
44
45 miniaturized systems for anticoagulant therapy monitoring.
46
47
48
49
50
51

52
53 The effect of heparin addition (0 – 2 U/mL) on plasma CT triggered by all ten aPTT
54
55 reagents in their liquid and dried forms was evaluated by TGA. Reagent sensitivity to
56
57 heparin was assessed on the basis of the derived calibration curves. For example, the
58
59
60

1
2
3
4 results for aPTT-P are shown in Fig. 4. The correlation between plasma CT and heparin
5 concentration was found to be linear for liquid and dried reagent with $R^2 > 0.98$.
6
7 However, the sensitivity to heparin was significantly different as evidenced by changes
8 in slope. The 14 day form was found to be the most responsive to anticoagulant in
9 which the CT increased by 392 s upon addition of heparin at 2 U/mL. In comparison,
10 CT values for liquid and 24 h dried reagent were prolonged by 127 s and 150 s,
11 respectively. The slope values illustrate the difference in heparin sensitivity: 62.2, 72.8
12 and 193.6 s.mL.U⁻¹ for liquid, 24 h and 14 days dried, respectively. However, it must
13 also be taken into account that the base CT (0 U/mL heparin) was significantly
14 increased due to drying from liquid (72 ±11 s) to 24 h (218 ±19 s) and 14 days (438
15 ±135 s), which suggested a significant deterioration in reagent activity. Therefore,
16 regardless of higher heparin sensitivity, such a reagent would not be suitable.
17 Furthermore, this reagent at 14 days yielded elevated %CV in comparison to the two
18 other tested forms (31% in comparison to 16% and 12% for liquid and 24 h dried
19 reagent, respectively).

20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40 **Fig. 4.**

41
42
43
44 Similar analyses were performed for the other reagents, the results of which are
45 summarised in Table 2. Addition of heparin resulted in the prolongation of CT for all
46 tested reagents. Some of these were significantly affected by the presence of heparin in
47 the sample, while others were less sensitive to its effect. The values obtained for liquid
48 reagents increased from 41 – 161 s for 0 U/mL heparin to 102 – 286 s, 130 – 348 s,
49 139 – 405 s and 199 – 810 s for 0.5, 0.75, 1 and 2 U/mL of heparin, respectively. CTs
50 obtained for 24 h dried reagent changed from 88 – 468 s to 138 – 602 s, 208 – 737 s,
51
52
53
54
55
56
57
58
59
60

1
2
3
4 186 – 880 s and 258 – 946 s with an increased heparin concentration. 14 day dried
5
6 reagents returned an increase in CT from 200 – 1566 s to 256 – 1517 s, 262 – 1439 s,
7
8 280 – 1705 s and 369 s – > 1 h with increasing heparin concentrations, respectively.
9
10 Although the issue of an increased base CT (0 U/mL heparin) occurred for all 14 day
11
12 dried reagents, this form was generally the most responsive to heparin. The exceptions
13
14 were Cephalinex, Dapttin and Alexin-HS for which the liquid form was the most
15
16 sensitive to heparin and Platelin LS which was significantly affected by the drying
17
18 process and 14 days of ambient storage resulted in the near complete loss of its potential
19
20 to reduce plasma CT; CT values obtained for plasma with 0 – 1 U/mL heparin were
21
22 1566 – 1640 s as compared to 1943 s for non-activated plasma. Generally, a trend of
23
24 prolonged CT with increased heparin concentration was observed. However, there was
25
26 great variation in the CT values for different aPTT reagents which suggested significant
27
28 differences in reagent quality.
29
30
31
32
33
34
35
36
37

38 The slope values in Table 2 indicate the differences in heparin sensitivity of the tested
39
40 reagents both in liquid and dried forms. It should be noted that the slope values obtained
41
42 for 14 day dried Platelin LS, Alexin and C.K. Prest 2 were quite high, but since no CT
43
44 was obtained for 2 U/mL heparin and the correlation was based on only four data points,
45
46 these reagents were excluded from the comparison of slope values for the 14 day dried
47
48 reagents. SynthASIL was shown to be by far the best performing in this respect,
49
50 yielding the highest slope values of 327.5, 312.1 and 443.1 s.mL.U⁻¹ for liquid, 24 h and
51
52 14 day dried forms, respectively. The non-heparinized plasma CTs of 161 ±24, 194 ±54
53
54 and 293 ±43 s were prolonged to 810 ±36, 806 ±35 and 1170 ±94 s, respectively, upon
55
56 addition of 2 U/mL of heparin. Such large differences in CT values (at least 600 s)
57
58
59
60

1
2
3
4 between non-heparinized and heparinized (2 U/mL) samples allowed good
5 discrimination between samples of different heparin levels. The least responsive to
6 heparin were aPTT-SA in liquid form (56.2 s.mL.U⁻¹), Alexin in 24 h dried form (48.7
7 s.mL.U⁻¹) and Cephalinex as 14 day dried reagent (56.5 s.mL.U⁻¹). These reagents
8 returned insignificant CT differences when tested over a range of heparin concentrations.
9 The use of these reagents in an anticoagulant monitoring device may result in the
10 diminished discrimination between heparin doses. For the purposes of a reagent for use
11 in a coagulation monitoring device, the activated CT is an extremely important factor
12 determining the assay time. The shortest CTs were achieved for Dapttin with 95 ±1 s for
13 non-heparinized plasma triggered with liquid reagent and 369 ±21 s for 2 U/mL heparin
14 in plasma triggered with 14 day dried reagent. The longest CTs were obtained for 14
15 day dried C.K. Prest 2, Platelin LS and Alexin for which an addition of heparin at 2
16 U/mL resulted in an enormously prolonged CT with which it was not possible to extract
17 a lag time.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 DISCUSSION

41
42 Very good linear correlations between CT and heparin concentration were found for
43 nine out of the ten tested reagents within the heparin range of 0 – 2 U/mL ($R^2 \geq 0.83$).
44 Platelin LS was the only reagent on which the drying process had a dramatic negative
45 impact resulting in significant loss of activity. High variation and no correlation with
46 increased heparin concentrations were also found for the 14 day dried samples ($R^2 =$
47 0.02). Even though most of the reagents tested responded to addition of heparin by
48 returning prolonged CTs, the deterioration of control clotting values (base CT) also had
49 to be taken into account when selecting a stable, dry formulation which was responsive
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 to heparin. Among several methodological factors influencing the aPTT performance,
5
6 the reagent composition is one of the most commonly cited (Manzato et al., 1998,
7
8 Shetty et al., 2003, Wojtkowski et al., 1999). The available surface area of the
9
10 negatively charged surface activators might be reduced due to dehydration following
11
12 drying. The surface activation may be influenced by the type of activator used. Drying
13
14 processes may have influenced the orientation and distribution of phospholipids. Some
15
16 classes of phospholipids are of particular importance, and depending on their ratios and
17
18 the total concentration of lipids, clotting can be promoted or inhibited (Slater et al.,
19
20 1980, Comfurius et al., 1994). Liquid reagents containing phospholipids derived from
21
22 rabbit brain cephalin (C.K. Prest 2, aPTT-P, aPTT-SA and Alexin) returned the shortest
23
24 CTs varying between 41 – 85 s. However, their ability to reduce plasma CT was
25
26 significantly impacted by the drying process. The chicken and porcine-derived
27
28 phospholipids used in Platelin LS gave an extremely prolonged CT in dried form (up to
29
30 1566 s for 14 days dried reagent). APTT-SP (silica and synthetic phospholipids) was the
31
32 only reagent for which the absolute CT did not increase after 24 h following drying.
33
34 However, prolonged storage under ambient conditions did result in the reagent's
35
36 eventual deterioration. Another reagent which performed reasonably well was
37
38 Cephalinex (containing silica activator and rabbit brain phospholipids). Despite the fact
39
40 that the 24 h drying did influence the reagent's ability to shorten plasma CT, the long
41
42 term storage did not seem to affect its activity. However, Cephalinex was shown to be
43
44 less sensitive to heparin than aPTT-SP in all three tested forms.
45
46
47
48
49
50
51
52
53
54
55

56 It has been also shown that the type and concentration of surface activator plays a major
57
58 role in the effectiveness of aPTT reagents (Marlar et al., 1984). Reagents based on
59
60

1
2
3
4 kaolin, (C.K. Prest 2) or kaolin/sulfatides (Dapttin) were shown to return rapid CTs in
5
6 all three tested forms, not exceeding 100 s for liquid, 130 s for 24 h dried and 300 s for
7
8 14 day dried forms. They were always among the five reagents with the shortest CTs.
9
10 The combination of traditionally-used kaolin and rabbit brain cephalin extract (C.K.
11
12 Prest 2) seemed to achieve rapid CTs. However, it should be taken into account that the
13
14 use of insoluble particulates such as kaolin or silica for automated devices employing
15
16 photo-optical detection may be problematic. The use of a soluble ellagic acid or a
17
18 mixture of low concentration insoluble activators such as kaolin and sulfatides i.e.
19
20 Dapttin (Moritz and Lang, 1995) may be a solution for devices based on optical
21
22 detection systems.
23
24
25
26
27
28
29

30 Although the reasons for the variable heparin sensitivity of the tested aPTT reagents
31
32 have not been determined, the nature of surface activator and lipid composition seem to
33
34 play a major role. The relationship between aPTT reagent lipid composition and heparin
35
36 sensitivity was thoroughly investigated by Kitchen et al. (1999). Van den Besselaar et al.
37
38 (1997) described a method of aPTT formulation preparation consisting of colloidal
39
40 silica and synthetic phospholipids and suggested that the synthetic reagents should form
41
42 a foundation for aPTT standardization of heparin therapeutic control. In fact, in our
43
44 study, synthetic phospholipid-based reagents (SynthASIL and aPTT-SP) performed
45
46 extremely well in terms of both heparin response and dried reagent stability. Additional
47
48 benefits of such homogeneous materials based on synthetic phospholipids includes
49
50 minimized batch-to-batch variability which leads to improvements in test CVs (Okuda
51
52 and Yamamoto, 2004). Both aPTT-SP and SynthASIL which are both based on
53
54 synthetic phospholipids and silica and are both manufactured by Hemosil, were
55
56
57
58
59
60

1
2
3
4 identified as promising candidates for incorporation into point of care diagnostic device
5
6
7 platforms as dried reagents.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

TABLES

Table 1. Panel of aPTT reagents including the manufacturers and the composition*.

Reagent	Producer	Surface Activator	Source of phospholipids
APTT-SP	<i>Hemosil</i>	Colloidal silica	Synthetic
Cephalinex	<i>BioData</i>	Microsilica	Rabbit brain
SynthASIL	<i>Hemosil</i>	Colloidal silica	Synthetic
Platelin LS	<i>BioMerieux</i>	Micronized silica	Porcine + chicken
C. K. Prest 2	<i>Diagnostica Stago</i>	Kaolin	Rabbit brain
Dapttin	<i>Technoclone</i>	Synthetic kaolin+sulfatides	Unknown
Alexin	<i>AMAX / Trinity Biotech</i>	Ellagic acid	Rabbit brain
Alexin-HS	<i>AMAX / Trinity Biotech</i>	Ellagic acid	Rabbit brain + soy
APTT-SA	<i>Helena BioSciences</i>	Ellagic acid	Rabbit brain
APTT-P	<i>Biopool</i>	Magnesium-aluminium-silicate	Rabbit brain

*Data is according to available manufacturer's information.

Table 2. aPTT reagents in liquid and dried forms (24 h and 14 days) characterized in terms of their heparin dose sensitivity (slope), normal derived CT (intercept), linear correlation with heparin from 0 to 2 U/ml (R^2), maximum standard deviation (SD) and maximum percentage coefficient of variation (CV).

Reagent	Form	Slope [s.mL.U ⁻¹]	Intercept [s]	R ²	Max. SD [s]	Max. CV [%]
aPTT-SP	Liquid	113.6	107.2	0.99	48	33
	24 h	84.0	96.2	0.99	63	44
	14 days	134.3	289.2	0.96	96	20
Cephalinex	Liquid	65.5	117.3	0.98	23	9
	24 h	57.8	261.6	0.83	68	22
	14 days	56.5	284.4	0.98	35	10
C.K. Prest 2	Liquid	95.0	51.9	0.98	22	31
	24 h	118.7	112.7	0.97	74	22
	14 days	561.8	249.0	0.99	106	13
SynthASIL	Liquid	327.5	123.6	0.98	36	15
	24 h	312.1	148.4	0.97	54	28
	14 days	443.1	260.2	0.99	94	15
Platelin LS	Liquid	68.6	103.6	0.98	22	22
	24 h	244.6	518.6	0.85	137	15
	14 days	(-53.2)	1516	0.02	416	27
aPTT-P	Liquid	62.2	77.5	0.99	11	16
	24 h	72.8	223.7	0.99	37	12
	14 days	193.6	457.4	0.99	135	31
aPTT-SA	Liquid	56.2	103.7	0.90	51	25
	24 h	83.8	196.0	0.98	84	29
	14 days	131.1	345.8	0.95	237	49
Dapttin	Liquid	105.1	96.3	1.0	49	16
	24 h	79.1	140.8	0.96	30	14
	14 days	82.1	203.6	0.99	49	17
Alexin	Liquid	61.4	86.6	1.0	7	8
	24 h	48.7	172.2	0.97	80	34
	14 days	829.5	867.4	0.98	359	27
Alexin-HS	Liquid	114.5	138.9	0.99	35	27
	24 h	83.3	118.8	0.95	49	14
	14 days	91.7	263.1	0.98	55	12

FIGURE LEGENDS

Fig. 1. Thrombin generation assay clotting profiles of Cephalinex in liquid (circles) and dried for 24 h (triangles) and 14 days (squares). Blank control was non-activated plasma (diamonds) (n = 3).

Fig. 2. The relationship between heparin concentration and CT as calculated using lag time (LT) and time to peak (TTP) for aPTT-SP in liquid and dried after 24 h. The trend line parameters were found to be as follows: TTP 24h dried (circles) $y = 102.32x + 255.83$, $R^2 = 0.986$; TTP liquid (reversed triangles) $y = 120.77x + 230.94$, $R^2 = 0.996$; LT 24h dried (squares) $y = 83.955x + 96.239$, $R^2 = 0.986$ and LT liquid (diamonds) $y = 116.18x + 88.045$, $R^2 = 0.997$.

Fig. 3. CT values obtained from plasmas activated with aPTT reagent; liquid (white), dried for 24 h (grey) and dried for 14 days (black) (n = 5).

Fig. 4. Relationship between heparin concentration and obtained CT for aPTT-P (n = 5). Plasma spiked with heparin (0 – 2 U/mL) was triggered with liquid (circles), 24 h dried (reversed triangles) and 14 days dried (squares) reagent. The trend line parameters obtained were as follows: $y = 62.182x + 77.545$, $R^2 = 0.9881$, $y = 72.818x + 223.7$, $R^2 = 0.9883$ and $y = 193.64x + 457.41$, $R^2 = 0.9858$ for liquid, 24 h and 14 day dried reagents, respectively.

1
2
3
4 ACKNOWLEDGMENTS
5
6
7

8
9 This material is based upon works supported by the Science Foundation Ireland under
10
11 Grant No. 05/CE3/B754.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

REFERENCES

- 1
2
3
4
5
6
7
8
9 BANEZ, E. I., TRIPLETT, D. A. & KOEPKE, J. (1980) Laboratory monitoring of
10
11 heparin therapy - The effect of different salts of heparin on the Activated Partial
12
13 Thromboplastin Time - An analysis of the 1978 and 1979 CAP hematology
14
15 survey. *American Journal of Clinical Pathology*, 74, 569-574.
16
17
18
19 BARROWCLIFFE, T. W. & GRAY, E. (1981) Studies of phospholipid reagents used in
20
21 coagulation. 2. Factors influencing their sensitivity to heparin. *Thrombosis and*
22
23 *Haemostasis*, 46, 634-637.
24
25
26 BEGUIN, S., LINDHOUT, T. & HEMKER, H. C. (1988) The mode of action of
27
28 heparin in plasma. *Thrombosis and Haemostasis*, 60, 457-462.
29
30
31 BOWERS, J. & FERGUSON, J. J. (1993) Use of the Activated Clotting Time in
32
33 anticoagulation monitoring of intravascular procedures. *Texas Heart Institute*
34
35 *Journal*, 20, 258-263.
36
37
38 COMFURIUS, P., SMEETS, E. F., WILLEMS, G. M., BEVERS, E. M. & ZWAAL, R.
39
40 F. A. (1994) Assembly of the prothrombinase complex on lipid vesicles depends
41
42 on the stereochemical configuration of the polar headgroup of
43
44 phosphatidylserine. *Biochemistry*, 33, 10319-10324.
45
46
47 EBY, C. (1997) Standardization of APTT reagents for heparin therapy monitoring:
48
49 Urgent or fading priority? *Clinical Chemistry*, 43, 1105-1107.
50
51
52 GAWOSKI, J. M., ARKIN, C. F., BOVILL, T., BRANDT, J., ROCK, W. A. &
53
54 TRIPLETT, D. A. (1987) The effects of heparin on the Activated Partial
55
56 Thromboplastin Time of the College of American Pathologists survey specimens
57
58
59
60

1
2
3
4 - Responsiveness, precision and sample effects. *Archives of Pathology &*
5
6 *Laboratory Medicine*, 111, 785-790.
7
8

9 GREAVES, M. (2004) Assessment of haemostasis. *Vox Sanguinis*, 87, 47-50.

10
11 GRIFFIN, J. H. & COCHRANE, C. G. (1979) Recent advances in the understanding of
12 the contact activation reactions. *Seminars in Thrombosis and Hemostasis*, 5,
13
14 254-273.
15
16
17

18 IP, B. K. H., THOMSON, A. R. & MORIARTY, H. T. (2001) A comparison of the
19 sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular
20 weight heparin. *Pathology*, 33, 347-352.
21
22
23
24

25 JESPERSEN, J., BERTINA, R. M. & HAVERKATE, F. (1999) *Laboratory techniques*
26 *in thrombosis: a manual* Springer.
27
28

29 KHAN, T. (2009) Point-of-care INR monitoring devices for patients on long-term oral
30 anticoagulation therapy. *Value in Health*, 12, A142-A142.
31
32
33

34 KHANDURINA, J. & GUTTMAN, A. (2002) Bioanalysis in microfluidic devices.
35
36 *Journal of Chromatography A*, 943, 159-183.
37
38

39 KITCHEN, S., CARTWRIGHT, I., WOODS, T. A. L., JENNINGS, I. & PRESTON, F.
40 E. (1999) Lipid composition of seven APTT reagents in relation to heparin
41 sensitivity. *British Journal of Haematology*, 106, 801-808.
42
43
44
45

46 KITCHEN, S., JENNINGS, I., WOODS, T. A. L. & PRESTON, F. E. (1996) Wide
47 variability in the sensitivity of APTT reagents for monitoring of heparin dosage.
48
49 *Journal of Clinical Pathology*, 49, 10-14.
50
51

52 LO, K., DENNEY, W. S. & DIAMOND, S. L. (2005) Stochastic modeling of blood
53 coagulation initiation. *Pathophysiology of Haemostasis and Thrombosis*, 34, 80-
54
55 90.
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- MANZATO, F., MENGONI, A., GRILENZONI, A. & LIPPI, G. (1998) Evaluation of the activated partial thromboplastin time (APTT) sensitivity to heparin using five commercial reagents: Implications for therapeutic monitoring. *Clinical Chemistry and Laboratory Medicine*, 36, 975-980.
- MARLAR, R. A., BAUER, P. J., ENDREBROOKS, J. L., MONTGOMERY, R. R., MILLER, C. M. & SCHANEN, M. M. (1984) Comparison of the sensitivity of commercial aPTT reagents in the detection of mild coagulopathies. *American Journal of Clinical Pathology*, 82, 436-439.
- MARTIN, B. A., BRANCH, D. W. & RODGERS, G. M. (1992) The preparation of a sensitive Partial Thromboplastin reagent from bovine brain. *Blood Coagulation & Fibrinolysis*, 3, 287-294.
- MORITZ, B. & LANG, H. (1995) APTT in a collective of plasmas from normal healthy individuals - Comparison of Daptin with other aPTT reagents. *Thrombosis and Haemostasis*, 73, 1243-1243.
- NEUENSCHWANDER, P. F., BIANCOFISHER, E., REZAIIE, A. R. & MORRISSEY, J. H. (1995) Phosphatidylethanolamine augments Factor VIIa-tissue factor activity - Enhancement of sensitivity to phosphatidylserine. *Biochemistry*, 34, 13988-13993.
- OKUDA, M. & YAMAMOTO, Y. (2004) Usefulness of synthetic phospholipid in measurement of activated partial thromboplastin time: a new preparation procedure to reduce batch difference. *Clinical and Laboratory Haematology*, 26, 215-223.
- POLLER, L., THOMSON, J. M. & TABERNER, D. A. (1989) Use of the Activated Partial Thromboplastin Time for monitoring heparin therapy - Problems and

possible solutions. *2nd International Symp on Standardization and Quality Control of Coagulation Tests : Implications for the Clinical Laboratory*. Rome, Italy.

SHETTY, S., GHOSH, K. & MOHANTY, D. (2003) Comparison of four commercially available activated partial thromboplastin time reagents using a semi-automated coagulometer. *Blood Coagulation & Fibrinolysis*, 14, 493-497.

SLATER, P. J., STEVENSON, K. J. & POLLER, L. (1980) Procoagulant activity of Partial Thromboplastin (cephalin) reagent and its phospholipid composition. *Thrombosis Research*, 18, 831-838.

SMEETS, E. F., COMFURIUS, P., BEVERS, E. M. & ZWAAL, R. F. A. (1996) Contribution of different phospholipid classes to the prothrombin converting capacity of sonicated lipid vesicles. *Thrombosis Research*, 81, 419-426.


STEVENSON, K. J., EASTON, A. C., CURRY, A., THOMSON, J. M. & POLLER, L. (1986) The reliability of Activated Partial Thromboplastin Time methods and the relationship to lipid composition and ultrastructure. *Thrombosis and Haemostasis*, 55, 250-258.

STEVENSON, K. J., POLLER, L. & THOMSON, J. M. (1991) The chemical composition, ultrastructure and procoagulant properties of 5 new aPTT reagents. *Thrombosis and Haemostasis*, 65, 906-906.

STRUVER, G. P. & BITTNER, D. L. (1962) Partial Thromboplastin Time (Cephalin Time) in anticoagulation therapy. *American Journal of Clinical Pathology*, 38, 473-&.

TRIPLETT, D. A. (1982) Sensitivity of activated partial thromboplastin time: results of the CAP survey and a series of mild and moderate factor deficiencies. IN

- 1
2
3
4 TRIPLETT, D. A. (Ed.) *Standardization of coagulation assays: an overview*.
5
6 College Of American Pathologists.
7
8
- 9 TS'AO, C., NEOFOTISTOS, D., OROPEZA, M., ROGAN, M. & SANTOS, M. (1998)
10
11 Performance characteristics of a new synthetic APTT reagent. *Clinical and*
12
13 *Laboratory Haematology*, 20, 307-313.
14
15
- 16 VAN VEEN, J. J., GATT, A. & MAKRIS, M. (2008) Thrombin generation testing in
17
18 routine clinical practice: are we there yet? *British Journal of Haematology*, 142,
19
20 889-903.
21
22
- 23 VANDENBESSELAAR, A., MEEUWISSEBRAUN, J. & BERTINA, R. M. (1990)
24
25 Monitoring heparin therapy - Relationships between the Activated Partial
26
27 Thromboplastin Time and heparin assays based on ex vivo heparin samples.
28
29 *Thrombosis and Haemostasis*, 63, 16-23.
30
31
- 32 VANDENBESSELAAR, A., NEUTEBOOM, J., MEEUWISSEBRAUN, J. &
33
34 BERTINA, R. M. (1997) Preparation of lyophilized partial thromboplastin time
35
36 reagent composed of synthetic phospholipids: Usefulness for monitoring heparin
37
38 therapy. *Clinical Chemistry*, 43, 1215-1222.
39
40
- 41 WOJTKOWSKI, T. A., RUTLEDGE, J. C. & MATTHEWS, D. C. (1999) The clinical
42
43 impact of increased sensitivity PT and APTT coagulation assays. *American*
44
45 *Journal of Clinical Pathology*, 112, 225-232.
46
47
- 48 WOLBERG, A. S. (2007) Thrombin generation assays: Understanding how the method
49
50 influences the results. *Thrombosis Research*, 119, 663-665.
51
52
53
54
55
56
57
58
59
60




611x484mm (150 x 150 DPI)

Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



615x473mm (150 x 150 DPI)

Review


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



604x553mm (150 x 150 DPI)



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



615x473mm (150 x 150 DPI)